萨尔瓦多2019年五联疫苗热性惊厥报告的信号检测
该研究回顾分析萨尔瓦多2011至2019年国家电子药品安全数据库的自发报告,采用不成比例分析评估五联疫苗接种后热性惊厥信号。结果显示2019年4月起热性惊厥报告率超过WHO预期,9月最高达9.2/10万剂,第一剂加强针率最高。提示存在安全性信号,可能与接种服务提供者变更有关。
要点
- 2019年萨尔瓦多五联疫苗后热性惊厥报告率超过WHO预期的6例/10万剂。
- 第一剂加强针热性惊厥率最高,为14.6/10万剂,超过预期两倍以上。
- 不成比例分析显示热性惊厥与五联疫苗存在信号,需进一步研究原因。
核心结论
- 2019年萨尔瓦多五联疫苗接种后热性惊厥报告存在不成比例,提示安全性信号。
- 信号可能与接种服务提供者变更有关,需进一步评估原因及成本效益。
研究设计与样本
- 回顾性观察研究,分析萨尔瓦多国家电子药品安全数据库2011至2019年不良事件报告。
- 采用不成比例分析计算PRR、ROR、RRR、卡方和信息成分(IC),比较2019年热性惊厥与五联疫苗配对与其他药物和不良事件。
主要发现
- 2019年4月起五联疫苗后热性惊厥发生率超过WHO预期的6例/10万剂,9月最高达9.2/10万剂。
- IC为4.3,ORR为421.9(95%CI:123.8-1437.7),PRR为223.5(95%CI:70.2-710.9),RRR为19.5。
- 第一剂加强针热性惊厥率最高,为14.6/10万剂,超过预期两倍以上;2018年率低于预期。
- 2014年以来全球五联疫苗后热性惊厥报告增加,2018和2019年率最高。
临床怎么用
- 监测五联疫苗接种后热性惊厥报告,尤其关注加强针接种后。
- 评估接种服务提供者变更对报告率的影响,并考虑换用反应原性较低的疫苗配方。
局限性
- 研究为回顾性观察,基于自发报告数据,可能存在报告偏倚。
- 未进一步分析热性惊厥增加的具体原因,需后续研究评估成本和效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Detection and surveillance of vaccine safety hazards is a public health staple. In the post-marketing phase, when vaccines are used in mass, it is crucial to monitor potential signals of adverse reactions that may have been missed in the pre-marketing phase. We analysed spontaneous reports of drug adverse events in El Salvador to assess a potential safety signal related to an increase in febrile seizures following the pentavalent (diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae Type B) vaccine in 2019. This was a retrospective observational study of adverse event notifications in the national electronic drug safety database from 2011 to 2019. We performed standard disproportionality analysis computing Proportional Reporting Risk (PRR), Reporting Odds Ratio (ROR), Relative Reporting Ratio (RRR), Chi-squared, and Information Component (IC), comparing the pairing of febrile seizures and pentavalent vaccine to all other drugs and adverse events recorded in 2019. The occurrence of febrile seizures following pentavalent vaccination exceeded the WHO expected rate of six cases × 100 000 doses administered from April 2019, with a maximum of 9.2 in September. IC was 4.3, ORR 421.9 (95% Confidence Interval, CI: 123.8-1437.7), PRR 223.5 (95 %CI: 70.2-710.9), RRR was 19.5. The first booster presented the highest rate (14.6 per 100,000 doses) of febrile seizures, more than double than expected. Rates for 2018 remained below expected. Reports of febrile seizures following pentavalent vaccine were also on the increase globally since 2014, with highest rates in 2018 and 2019. There was a disproportion of febrile seizures notifications following pentavalent in El Salvador in 2019, suggesting the existence of a safety signal. This may be due to the change in provider. Further studies should assess the causes of the increase and compute costs and benefits of this vaccination to determine if switching to a less reactogenic vaccine formulation is indicated.
引用
- Elas M, Villatoro N, Pezzoli L, et al. Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador. Vaccine. 2021. PMID: 34275672. doi:10.1016/j.vaccine.2021.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。